Tenderwize
Zurück zur Suche

Open house drug discount agreements Nintedanib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Structured notice only
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nintedanib, ATC L01EX09

40/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

40 / 100

Komplexität

20 / 100

Risikofaktoren

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive discount agreements for Nintedanib (ATC L01EX09) with pharmaceutical companies in Bavaria.
  • Open-house model: any eligible pharmaceutical company can join without selection.
Vollständige Zusammenfassung anzeigen

Open-house model for non-exclusive drug discount agreements for Nintedanib (ATC L01EX09) by AOK Bayern. Not subject to procurement law. Contracts are offered to all interested pharmaceutical companies that meet eligibility criteria. No selection or award criteria. Contracts run from May 2026 to April 2028, with possible early termination. No estimated value provided.

Risiken

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Eligibility: only pharmaceutical companies; submit signed self-declaration of reliability.

Administrative

  • Submission: either signed paper copy (two originals) or electronically with qualified electronic signature via DTVP portal.
  • Documents: completed and signed contract, annex listing medicines, and self-declaration of reliability.

Anforderungen können unvollständig sein.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house drug discount agreements Nintedanib

Non-exclusive discount agreements for the active substance Nintedanib (ATC L01EX09) under §130a(8) SGB V. All eligible pharmaceutical companies can join. Identical, non-negotiable terms. Contracts run from 01.05.2026 to 30.04.2028. Early termination possible with one month notice. Automatic suspension if a competitive discount contract is concluded.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Apr 2026 - Apr 2028

Kategorie

Pharmaceutical products

Frist

Deadline Mar 03, 2028

Vergabedetails

Veröffentlichungsdatum
15 Mar 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
181186-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30